Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8330899 | 0.84 | ALDH1A1 (0.42) | ALDH1A1TGFBR1TET2EGLN1CA12 | |
| SCHEMBL3951015 | 0.77 | ALDH1A1 (0.45) | ALDH1A1EGLN1TSHR | |
| Sulfuric Acid SCHEMBL27665149 | 0.74 | ALDH1A1 (0.42) | ALDH1A1TGFBR1TET2EGLN1CA12 | |
| SCHEMBL17424802 | 0.74 | TSHR (0.48) | ALDH1A1TSHR | |
| SCHEMBL17424814 | 0.74 | THRB (0.46) | ALDH1A1TSHR | |
| SCHEMBL11603931 | 0.74 | ALDH1A1 (0.52) | ALDH1A1TGFBR1TET2EGLN1CA12 | |
| SCHEMBL23095593 | 0.73 | THRB (0.41) | ALDH1A1CA12TSHR | |
| Sulfuric Acid SCHEMBL27509967 | 0.73 | ALDH1A1 (0.41) | ALDH1A1TGFBR1TET2EGLN1CA12 | |
| SCHEMBL4904944 | 0.72 | TET2 (0.39) | TET2 | |
| SCHEMBL36299 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116332900-B | Olefin compound and synthesis method thereof | 华中科技大学 | 2024-12-06 | — | — | CN | claimed |
| CN-116332900-A | Olefin compound and synthesis method thereof | 华中科技大学 | 2023-06-27 | — | — | CN | disclosed |
| US-20080103311-A1 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103311-A1 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103311-A1 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-7312333-B2 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312333-B2 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312333-B2 | Retroviral protease inhibitors | PHARMACIA CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| US-20060264483-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-11-23 | — | — | US | disclosed |
| US-20060166895-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (NOW NAMED PHARMACIA CORPORATION, WHICH IS A WHOLLY OWNED SUBSIDIARY OF PFIZER, INC (US) | 2006-07-27 | — | — | US | disclosed |
| EP-0558603-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558630-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558673-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558657-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0554400-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-08-11 | — | — | EP | disclosed |
| WO-1992008701-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008700-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008699-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008688-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008698-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103311-A1 | Retroviral protease inhibitors | PREP, DNPEP, SERPINB1 | ALDH1A1 2859/4885TGFBR1 4246/4885TET2 3289/4885 |
| US-20060264483-A1 | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, PRSS1 | ALDH1A1 3190/4885TGFBR1 4510/4885TET2 3750/4885 |
| US-20060166895-A1 | Retroviral protease inhibitors | MME, PREP, TMPRSS15 | ALDH1A1 2763/4885TGFBR1 4490/4885TET2 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.